SEC Form 4 · accession 0001553350-26-000111
Starling Oncology, Inc. · STLN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Yale Podnos
Officer — Chief Medical Officer
Period of report
Jul 14, 2026
Accepted (ET)
Jul 16, 2026 · 8:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001799191
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 14, 2026 | M | 17,974 | $1.87 | A | 277,501 | D | |
| Common Stock | Jul 14, 2026 | S | 17,974 | $6.429 | D | 259,527 | D | |
| Common Stock | Jul 14, 2026 | M | 5,478 | $2.00 | A | 265,005 | D | |
| Common Stock | Jul 14, 2026 | S | 5,478 | $6.35 | D | 259,527 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $1.87 | Jul 14, 2026 | M | 17,974 | A | — | Nov 17, 2032 | Common Stock | 17,974 | 0 | D |
| Stock Option (Right to Buy)F2 | $2.00 | Jul 14, 2026 | M | 5,478 | A | — | May 21, 2034 | Common Stock | 5,478 | 0 | D |
Explanation of responses
- F1The sale transactions were effected pursuant to a Rule 10(b) 5-1 trading plan adopted by the Reporting Person on 08/26/2025.
- F2The stock options described above were originally granted on 11/17/2022 and 05/21/2024, respectively, and vested in accordance with their respective terms.
- F3The sales reported in Table I reflect shares acquired upon exercise of the options identified in Table II, sold on the same day pursuant to the 10(b) 5-1 plan referenced in Footnote 1.